At present, the most widely known tyrosine kinase inhibitor (TKI) targets in NSCLC-NOS are EGFR activating mutations, 90% of which consist of in-frame deletions in exon 19 and the L858R point mutation in exon 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.